| Literature DB >> 25656130 |
Abstract
Peritoneal metastasis is considered as the end stage of gastric cancer, which is a fatal malignancy without the chance of surgery. No standard regimens are recommended. Routine treatments can not improve the survival of these patients, while multidisciplinary treatments may probably be promising. Aggressive treatments such as cytoreductive surgery, intra-peritoneal chemotherapy and bidirectional chemotherapy are applied to clinical management in recent years. Furthermore, molecular targeted therapy and immune therapy are developed and making individualized treatment possible. Individualized treatment according to clinical characteristics and expression of biomarkers will be the future of peritoneal metastasis of gastric cancer.Entities:
Mesh:
Year: 2015 PMID: 25656130
Source DB: PubMed Journal: Zhonghua Wei Chang Wai Ke Za Zhi ISSN: 1671-0274